Metabolomic therapy response prediction in pretherapeutic tissue biopsies for trastuzumab in patients with HER2‐positive advanced gastric cancer

Código QR

Metabolomic therapy response prediction in pretherapeutic tissue biopsies for trastuzumab in patients with HER2‐positive advanced gastric cancer

Guardado en:

Detalles Bibliográficos
Autores principales:	Thomas Kunzke, Fabian T. Hölzl, Verena M. Prade, Achim Buck, Katharina Huber, Annette Feuchtinger, Karolin Ebert, Gwen Zwingenberger, Robert Geffers, Stefanie M. Hauck, Ivonne Haffner, Birgit Luber, Florian Lordick, Axel Walch
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2021
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/a209e45f32244846aabeedb91561d7bf
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Liquid biopsy identifies actionable dynamic predictors of resistance to Trastuzumab Emtansine (T-DM1) in advanced HER2-positive breast cancer
por: Matteo Allegretti, et al.
Publicado: (2021)

Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models
por: Jamunarani Veeraraghavan, et al.
Publicado: (2021)

Elbow Stiffness Imaging: A Practical Diagnostic and Pretherapeutic Approach
por: Charles Lombard, et al.
Publicado: (2021)

Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer
por: Oostra DR, et al.
Publicado: (2014)

Trastuzumab emtansine in the treatment of HER2-positive metastatic breast cancer in Japanese patients
por: Sawaki M
Publicado: (2014)

Association between HSP90 and Her2 in gastric and gastroesophageal carcinomas.
por: Sabina Berezowska, et al.
Publicado: (2013)

An integrated stress response via PKR suppresses HER2+ cancers and improves trastuzumab therapy
por: Cedric Darini, et al.
Publicado: (2019)

Caveolin-1 mediates cellular distribution of HER2 and affects trastuzumab binding and therapeutic efficacy
por: Patrícia M. R. Pereira, et al.
Publicado: (2018)

Targeted delivery of doxorubicin-utilizing chitosan nanoparticles surface-functionalized with anti-Her2 trastuzumab
por: Yousefpour P, et al.
Publicado: (2011)

PTEN is a predictive biomarker of trastuzumab resistance and prognostic factor in HER2-overexpressing gastroesophageal adenocarcinoma
por: Daiju Yokoyama, et al.
Publicado: (2021)

Trastuzumab for Her2/neu-positive metastatic salivary gland carcinoma: Case report and review of the literature
por: Belal Firwana, et al.
Publicado: (2012)

The Long-HER study: clinical and molecular analysis of patients with HER2+ advanced breast cancer who become long-term survivors with trastuzumab-based therapy.
por: Angelo Gámez-Pozo, et al.
Publicado: (2014)

Combination of 131I-trastuzumab and lanatoside C enhanced therapeutic efficacy in HER2 positive tumor model
por: Nagarajan Vinod, et al.
Publicado: (2021)

Combination of Near-Infrared Photoimmunotherapy Using Trastuzumab and Small Protein Mimetic for HER2-Positive Breast Cancer
por: Haruka Yamaguchi, et al.
Publicado: (2021)

The efficacy of the combination of eribulin and trastuzumab in advanced HER2-positive breast cancer: the results of Russian observational study
por: Elena I. Kovalenko, et al.
Publicado: (2020)

Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer
por: Laura M. Spring, et al.
Publicado: (2021)

Spotlight on Trastuzumab Deruxtecan (DS-8201,T-DXd) for HER2 Mutation Positive Non-Small Cell Lung Cancer
por: Azar I, et al.
Publicado: (2021)

Profile of Trastuzumab Deruxtecan in the Management of Patients with HER2-Positive Unresectable or Metastatic Breast Cancer: An Evidence-Based Review
por: Linehan AS, et al.
Publicado: (2021)

A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients
por: Huiping Li, et al.
Publicado: (2018)

Influence of Ile655Val polymorphism on trastuzumab-induced cardiotoxicity in early-stage HER2 positive breast cancer
por: Ljubica Vazdar, et al.
Publicado: (2021)

Combination of Pertuzumab and Trastuzumab in the Treatment of HER2-Positive Early Breast Cancer: A Review of the Emerging Clinical Data
por: Jagosky M, et al.
Publicado: (2021)

Impact of dose-dense neoadjuvant chemotherapy on pathologic response and survival for HER2-positive breast cancer patients who receive trastuzumab
por: Lize Wang, et al.
Publicado: (2021)

The Role of Trastuzumab in Patients with HER2 Positive Small (pT1mi/a) Breast Cancers, a Multicenter Retrospective Study
por: Andrea Villasco, et al.
Publicado: (2021)

Hyperactivation of HER2-SHCBP1-PLK1 axis promotes tumor cell mitosis and impairs trastuzumab sensitivity to gastric cancer
por: Wengui Shi, et al.
Publicado: (2021)

Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial
por: Amy S. Clark, et al.
Publicado: (2021)

Role in staging and prognostic value of pretherapeutic F-18 FDG PET/CT in patients with gastric MALT lymphoma without high-grade transformation
por: Yong-Jin Park, et al.
Publicado: (2021)

2D-echocardiography vs cardiac MRI strain: a prospective cohort study in patients with HER2-positive breast cancer undergoing trastuzumab
por: Nathalie I. Bouwer, et al.
Publicado: (2021)

Multimodal Imaging Technology Effectively Monitors HER2 Expression in Tumors Using Trastuzumab-Coupled Organic Nanoparticles in Patient-Derived Xenograft Mice Models
por: Li Wen, et al.
Publicado: (2021)

Pathological Complete Response with Neoadjuvant Trastuzumab Combined with Chemotherapy in HER2 Positive Breast Cancer: A Single Institution Retrospective Analysis from Vietnam
por: Phung HT, et al.
Publicado: (2020)

Towards integration of 64Cu-DOTA-trastuzumab PET-CT and MRI with mathematical modeling to predict response to neoadjuvant therapy in HER2 + breast cancer
por: Angela M. Jarrett, et al.
Publicado: (2020)

A Case of Multiple Liver Metastases after Surgery in Elderly HER2-Positive Breast Cancer in Which Anastrozole + Trastuzumab Was Ineffective but T-DM1 Was Effective
por: Tomohiro Shidahara, et al.
Publicado: (2021)

Functionalized immunostimulating complexes with protein A via lipid vinyl sulfones to deliver cancer drugs to trastuzumab-resistant HER2-overexpressing breast cancer cells
por: Rodríguez-Serrano F, et al.
Publicado: (2016)

Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07)
por: Sara A. Hurvitz, et al.
Publicado: (2020)

Investigation of antitumor activities of trastuzumab delivered by PLGA nanoparticles
por: Colzani B, et al.
Publicado: (2018)

Efficacy with Trastuzumab Deruxtecan for Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutation in a Patient with a Poor Performance Status: A Case Report
por: Kato Y, et al.
Publicado: (2021)

Molecular Progression of Myeloproliferative and Myelodysplastic/Myeloproliferative Neoplasms: A Study on Sequential Bone Marrow Biopsies
por: Magdalena M. Brune, et al.
Publicado: (2021)

Native glycan fragments detected by MALDI mass spectrometry imaging are independent prognostic factors in pancreatic ductal adenocarcinoma
por: Na Sun, et al.
Publicado: (2021)

The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
por: Avisek Majumder, et al.
Publicado: (2021)

Reversible cardiotoxicity in a 54-year-old woman treated with trastuzumab
por: Martins,Sandro José, et al.
Publicado: (2012)

Primary systemic therapy in HER2-positive operable breast cancer using trastuzumab and chemotherapy: efficacy data, cardiotoxicity and long-term follow-up in 142 patients diagnosed from 2005 to 2016 at a single institution
por: Antolín S, et al.
Publicado: (2018)